바이오엔지니어링 단백질 의약품 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 전망(2024-2034년)
Bioengineered Protein Drugs Market (Disease Condition: Cancer, Diabetes, Autoimmune Disorder, Infectious Disease, Hematopoiesis, CVD, Neurodegenerative, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2024-2034
상품코드:1487571
리서치사:Transparency Market Research
발행일:2024년 04월
페이지 정보:영문 202 Pages
라이선스 & 가격 (부가세 별도)
한글목차
바이오엔지니어링 단백질 의약품 시장- 조사 범위
TMR의 세계 바이오엔지니어링 단백질 의약품 시장 조사 보고서는 2024년부터 2034년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회도 조사했습니다. 이 보고서는 2024년을 기준연도로, 2034년을 예측 연도로 하여 2018년부터 2034년까지 세계 바이오엔지니어링 단백질 의약품 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계 바이오엔지니어링 단백질 의약품 시장의 연평균 성장률(CAGR%)을 제시합니다.
이 보고서는 광범위한 조사를 통해 작성되었으며, 1차 조사에서는 KOL(Key Opinion Leader), 업계 리더 및 오피니언 제조업체를 인터뷰하고, 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 문서 등을 참조하여 생명공학 단백질 의약품 시장을 이해했습니다..
시장 현황
2023년 시장 규모
3,471억 달러
2034년 시장 가치
6,727억 달러
CAGR
6.2%
이 보고서는 세계 바이오엔지니어링 단백질 의약품 시장의 경쟁 환경을 조사했습니다. 세계 바이오 엔지니어드 단백질 의약품 시장에서 활동하는 주요 기업이 확인되었으며, 각 기업은 다양한 속성으로 프로파일링되었습니다. 기업 개요, 재무 상태, 최근 동향 및 SWOT는 이 보고서에서 프로파일링된 세계 바이오엔지니어링 단백질 의약품 시장 기업의 속성입니다.
목차
제1장 서문
제2장 전제조건과 조사 방법
제3장 주요 요약 : 시장
제4장 시장 개요
서론
시장 개요
시장 역학
시장 분석과 예측, 2020-2034년
제5장 주요 인사이트
파이프라인 분석
주요 제품 및 브랜드 분석
주요 M&A
COVID-19 팬데믹의 산업에 대한 영향
제6장 세계 시장 분석과 예측 : 약제 유형별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 약제 유형별, 2020-2034년
단클론항체
Humira
Rituxan
Avastin
Herceptin
Remicade
Lucentis
Enbrel
Synazis
기타
치료용 단백질
호르몬
사이토카인
Neupogen
Neulasta
Interferon Alpha
Erythropoietin Alpha
Interleukin
기타
혈액 인자
효소 요법
전신 효소 요법
소화 효소 요법
혈전용해제
tPA
Systemic Enzyme Therapy
Digestive Enzyme Therapy
백신
시장의 매력 분석 : 약제 유형별
제7장 세계 시장 분석과 예측 : 질환별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 질환별, 2020-2034년
암
당뇨병
자가면역질환
감염증
조혈
CVD
신경 변성
기타
시장의 매력 분석 : 질환별
제8장 세계 시장 분석과 예측 : 최종사용자별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 최종사용자별, 2020-2034년
제약 기업 및 바이오테크놀러지 기업
CRO
연구기관
시장의 매력 분석 : 최종사용자별
제9장 세계 시장 분석과 예측 : 지역별
주요 조사 결과
시장 매출 예측 : 지역별, 2020-2034년
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
시장의 매력 분석 : 지역별
제10장 북미 시장 분석과 예측
제11장 유럽 시장 분석과 예측
제12장 아시아태평양 시장 분석과 예측
제13장 라틴아메리카 시장 분석과 전망
제14장 중동 및 아프리카 시장 분석과 전망
제15장 경쟁 구도
시장 경쟁 매트릭스(기업 Tier별, 기업 규모별)
시장 점유율 분석 : 기업별(2023년)
기업 개요
Abbott
Amgen Inc.
Bayer AG
Biocon
Dr. Reddy's Laboratories
Lilly
F. Hoffmann-La Roche Ltd.
Fresenius Kabi AG
GSK
Janssen Global Services
Merck & Co., Inc.
Novartis AG
Panacea Biotec
ProBioGen AG
Reliance Life Science
Sanofi
LSH
영문 목차
영문목차
Bioengineered Protein Drugs Market - Scope of Report
TMR's report on the global bioengineered protein drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global bioengineered protein drugs market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global bioengineered protein drugs market from 2024 to 2034.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the bioengineered protein drugs market.
Market Snapshot
Market Value in 2023
US$ 347.1 Bn
Market Value in 2034
US$ 672.7 Bn
CAGR
6.2%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global bioengineered protein drugs market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global bioengineered protein drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global bioengineered protein drugs market.
The report delves into the competitive landscape of the global bioengineered protein drugs market. Key players operating in the global bioengineered protein drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global bioengineered protein drugs market profiled in this report.
Key Questions Answered in Global bioengineered protein drugs Market Report:
What is the sales/revenue generated by bioengineered protein drugs across all regions during the forecast period?
What are the opportunities in the global bioengineered protein drugs market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2034?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Bioengineered Protein Drugs Market - Research Objectives and Research Approach
The comprehensive report on the global bioengineered protein drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global bioengineered protein drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global bioengineered protein drugs market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Bioengineered Protein Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Bioengineered Protein Drugs Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Bioengineered Protein Drugs Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Type, 2020-2034
6.3.1. Monoclonal Antibodies
6.3.1.1. Humira
6.3.1.2. Rituxan
6.3.1.3. Avastin
6.3.1.4. Herceptin
6.3.1.5. Remicade
6.3.1.6. Lucentis
6.3.1.7. Enbrel
6.3.1.8. Synazis
6.3.1.9. Others
6.3.2. Therapeutic Proteins
6.3.2.1. Hormones
6.3.2.2. Cytokines
6.3.2.2.1. Neupogen
6.3.2.2.2. Neulasta
6.3.2.2.3. Interferon Alpha
6.3.2.2.4. Erythropoietin Alpha
6.3.2.2.5. Interleukin
6.3.2.2.6. Others
6.3.3. Blood Factor
6.3.4. Enzyme Therapy
6.3.4.1. Systemic Enzyme Therapy
6.3.4.2. Digestive Enzyme Therapy
6.3.5. Thrombolytics
6.3.5.1. tPA
6.3.5.2. Streptokinase
6.3.5.3. Urokinase
6.3.6. Vaccines
6.4. Market Attractiveness Analysis, by Drug Type
7. Global Bioengineered Protein Drugs Market Analysis and Forecast, by Disease Condition
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Disease Condition, 2020-2034
7.3.1. Cancer
7.3.2. Diabetes
7.3.3. Autoimmune Disorder
7.3.4. Infectious Disease
7.3.5. Hematopoiesis
7.3.6. CVD
7.3.7. Neurodegenerative
7.3.8. Others
7.4. Market Attractiveness Analysis, by Disease Condition
8. Global Bioengineered Protein Drugs Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2020-2034
8.3.1. Pharma and Biotech Companies
8.3.2. CROs
8.3.3. Research Institutes
8.4. Market Attractiveness Analysis, by End-user
9. Global Bioengineered Protein Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Bioengineered Protein Drugs Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Type, 2020-2034
10.3.1. Monoclonal Antibodies
10.3.1.1. Humira
10.3.1.2. Rituxan
10.3.1.3. Avastin
10.3.1.4. Herceptin
10.3.1.5. Remicade
10.3.1.6. Lucentis
10.3.1.7. Enbrel
10.3.1.8. Synazis
10.3.1.9. Others
10.3.2. Therapeutic Proteins
10.3.2.1. Hormones
10.3.2.2. Cytokines
10.3.2.2.1. Neupogen
10.3.2.2.2. Neulasta
10.3.2.2.3. Interferon Alpha
10.3.2.2.4. Erythropoietin Alpha
10.3.2.2.5. Interleukin
10.3.2.2.6. Others
10.3.3. Blood Factor
10.3.4. Enzyme Therapy
10.3.4.1. Systemic Enzyme Therapy
10.3.4.2. Digestive Enzyme Therapy
10.3.5. Thrombolytics
10.3.5.1. tPA
10.3.5.2. Streptokinase
10.3.5.3. Urokinase
10.3.6. Vaccines
10.4. Market Value Forecast, by Disease Condition, 2020-2034
10.4.1. Cancer
10.4.2. Diabetes
10.4.3. Autoimmune Disorder
10.4.4. Infectious Disease
10.4.5. Hematopoiesis
10.4.6. CVD
10.4.7. Neurodegenerative
10.4.8. Others
10.5. Market Value Forecast, by End-user, 2020-2034
10.5.1. Pharma and Biotech Companies
10.5.2. CROs
10.5.3. Research Institutes
10.6. Market Value Forecast, by Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Drug Type
10.7.2. By Disease Condition
10.7.3. By End-user
10.7.4. By Country
11. Europe Bioengineered Protein Drugs Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Type, 2020-2034
11.3.1. Monoclonal Antibodies
11.3.1.1. Humira
11.3.1.2. Rituxan
11.3.1.3. Avastin
11.3.1.4. Herceptin
11.3.1.5. Remicade
11.3.1.6. Lucentis
11.3.1.7. Enbrel
11.3.1.8. Synazis
11.3.1.9. Others
11.3.2. Therapeutic Proteins
11.3.2.1. Hormones
11.3.2.2. Cytokines
11.3.2.2.1. Neupogen
11.3.2.2.2. Neulasta
11.3.2.2.3. Interferon Alpha
11.3.2.2.4. Erythropoietin Alpha
11.3.2.2.5. Interleukin
11.3.2.2.6. Others
11.3.3. Blood Factor
11.3.4. Enzyme Therapy
11.3.4.1. Systemic Enzyme Therapy
11.3.4.2. Digestive Enzyme Therapy
11.3.5. Thrombolytics
11.3.5.1. tPA
11.3.5.2. Streptokinase
11.3.5.3. Urokinase
11.3.6. Vaccines
11.4. Market Value Forecast, by Disease Condition, 2020-2034
11.4.1. Cancer
11.4.2. Diabetes
11.4.3. Autoimmune Disorder
11.4.4. Infectious Disease
11.4.5. Hematopoiesis
11.4.6. CVD
11.4.7. Neurodegenerative
11.4.8. Others
11.5. Market Value Forecast, by End-user, 2020-2034
11.5.1. Pharma and Biotech Companies
11.5.2. CROs
11.5.3. Research Institutes
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Drug Type
11.7.2. By Disease Condition
11.7.3. By End-user
11.7.4. By Country/Sub-region
12. Asia Pacific Bioengineered Protein Drugs Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Type, 2020-2034
12.3.1. Monoclonal Antibodies
12.3.1.1. Humira
12.3.1.2. Rituxan
12.3.1.3. Avastin
12.3.1.4. Herceptin
12.3.1.5. Remicade
12.3.1.6. Lucentis
12.3.1.7. Enbrel
12.3.1.8. Synazis
12.3.1.9. Others
12.3.2. Therapeutic Proteins
12.3.2.1. Hormones
12.3.2.2. Cytokines
12.3.2.2.1. Neupogen
12.3.2.2.2. Neulasta
12.3.2.2.3. Interferon Alpha
12.3.2.2.4. Erythropoietin Alpha
12.3.2.2.5. Interleukin
12.3.2.2.6. Others
12.3.3. Blood Factor
12.3.4. Enzyme Therapy
12.3.4.1. Systemic Enzyme Therapy
12.3.4.2. Digestive Enzyme Therapy
12.3.5. Thrombolytics
12.3.5.1. tPA
12.3.5.2. Streptokinase
12.3.5.3. Urokinase
12.3.6. Vaccines
12.4. Market Value Forecast, by Disease Condition, 2020-2034
12.4.1. Cancer
12.4.2. Diabetes
12.4.3. Autoimmune Disorder
12.4.4. Infectious Disease
12.4.5. Hematopoiesis
12.4.6. CVD
12.4.7. Neurodegenerative
12.4.8. Others
12.5. Market Value Forecast, by End-user, 2020-2034
12.5.1. Pharma and Biotech Companies
12.5.2. CROs
12.5.3. Research Institutes
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Drug Type
12.7.2. By Disease Condition
12.7.3. By End-user
12.7.4. By Country/Sub-region
13. Latin America Bioengineered Protein Drugs Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Type, 2020-2034
13.3.1. Monoclonal Antibodies
13.3.1.1. Humira
13.3.1.2. Rituxan
13.3.1.3. Avastin
13.3.1.4. Herceptin
13.3.1.5. Remicade
13.3.1.6. Lucentis
13.3.1.7. Enbrel
13.3.1.8. Synazis
13.3.1.9. Others
13.3.2. Therapeutic Proteins
13.3.2.1. Hormones
13.3.2.2. Cytokines
13.3.2.2.1. Neupogen
13.3.2.2.2. Neulasta
13.3.2.2.3. Interferon Alpha
13.3.2.2.4. Erythropoietin Alpha
13.3.2.2.5. Interleukin
13.3.2.2.6. Others
13.3.3. Blood Factor
13.3.4. Enzyme Therapy
13.3.4.1. Systemic Enzyme Therapy
13.3.4.2. Digestive Enzyme Therapy
13.3.5. Thrombolytics
13.3.5.1. tPA
13.3.5.2. Streptokinase
13.3.5.3. Urokinase
13.3.6. Vaccines
13.4. Market Value Forecast, by Disease Condition, 2020-2034
13.4.1. Cancer
13.4.2. Diabetes
13.4.3. Autoimmune Disorder
13.4.4. Infectious Disease
13.4.5. Hematopoiesis
13.4.6. CVD
13.4.7. Neurodegenerative
13.4.8. Others
13.5. Market Value Forecast, by End-user, 2020-2034
13.5.1. Pharma and Biotech Companies
13.5.2. CROs
13.5.3. Research Institutes
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Drug Type
13.7.2. By Disease Condition
13.7.3. By End-user
13.7.4. By Country/Sub-region
14. Middle East & Africa Bioengineered Protein Drugs Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Drug Type, 2020-2034
14.3.1. Monoclonal Antibodies
14.3.1.1. Humira
14.3.1.2. Rituxan
14.3.1.3. Avastin
14.3.1.4. Herceptin
14.3.1.5. Remicade
14.3.1.6. Lucentis
14.3.1.7. Enbrel
14.3.1.8. Synazis
14.3.1.9. Others
14.3.2. Therapeutic Proteins
14.3.2.1. Hormones
14.3.2.2. Cytokines
14.3.2.2.1. Neupogen
14.3.2.2.2. Neulasta
14.3.2.2.3. Interferon Alpha
14.3.2.2.4. Erythropoietin Alpha
14.3.2.2.5. Interleukin
14.3.2.2.6. Others
14.3.3. Blood Factor
14.3.4. Enzyme Therapy
14.3.4.1. Systemic Enzyme Therapy
14.3.4.2. Digestive Enzyme Therapy
14.3.5. Thrombolytics
14.3.5.1. tPA
14.3.5.2. Streptokinase
14.3.5.3. Urokinase
14.3.6. Vaccines
14.4. Market Value Forecast, by Disease Condition, 2020-2034
14.4.1. Cancer
14.4.2. Diabetes
14.4.3. Autoimmune Disorder
14.4.4. Infectious Disease
14.4.5. Hematopoiesis
14.4.6. CVD
14.4.7. Neurodegenerative
14.4.8. Others
14.5. Market Value Forecast, by End-user, 2020-2034
14.5.1. Pharma and Biotech Companies
14.5.2. CROs
14.5.3. Research Institutes
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Drug Type
14.7.2. By Disease Condition
14.7.3. By End-user
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
